company background image
ZVA logo

Cellectis DB:ZVA Stock Report

Last Price

€2.34

Market Cap

€177.8m

7D

6.5%

1Y

21.7%

Updated

27 Mar, 2024

Data

Company Financials +

ZVA Stock Overview

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells.

ZVA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Cellectis S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cellectis
Historical stock prices
Current Share Price€2.34
52 Week High€3.19
52 Week Low€0.88
Beta3.13
1 Month Change-7.15%
3 Month Change-22.50%
1 Year Change21.67%
3 Year Change-85.40%
5 Year Change-85.98%
Change since IPO-82.70%

Recent News & Updates

Recent updates

Shareholder Returns

ZVADE BiotechsDE Market
7D6.5%2.1%1.9%
1Y21.7%37.0%7.3%

Return vs Industry: ZVA underperformed the German Biotechs industry which returned 37% over the past year.

Return vs Market: ZVA exceeded the German Market which returned 7.3% over the past year.

Price Volatility

Is ZVA's price volatile compared to industry and market?
ZVA volatility
ZVA Average Weekly Movement7.7%
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: ZVA's share price has been volatile over the past 3 months.

Volatility Over Time: ZVA's weekly volatility has decreased from 27% to 8% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1999234Andre Choulikahttps://www.cellectis.com

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL.

Cellectis S.A. Fundamentals Summary

How do Cellectis's earnings and revenue compare to its market cap?
ZVA fundamental statistics
Market cap€177.80m
Earnings (TTM)-€66.40m
Revenue (TTM)€22.65m

7.8x

P/S Ratio

-2.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ZVA income statement (TTM)
RevenueUS$24.53m
Cost of RevenueUS$1.26m
Gross ProfitUS$23.26m
Other ExpensesUS$95.15m
Earnings-US$71.89m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.00
Gross Margin94.86%
Net Profit Margin-293.13%
Debt/Equity Ratio41.4%

How did ZVA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.